DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,280 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
Follow-Up Questions
Who is the CEO of DiaSorin SpA?
Mr. Carlo Rosa is the Chief Executive Officer of DiaSorin SpA, joining the firm since 1998.
What is the price performance of DSRLF stock?
The current price of DSRLF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for DiaSorin SpA?
DiaSorin SpA belongs to Health Care industry and the sector is Health Care
What is DiaSorin SpA market cap?
DiaSorin SpA's current market cap is $0
Is DiaSorin SpA a buy, sell, or hold?
According to wall street analysts, 18 analysts have made analyst ratings for DiaSorin SpA, including 4 strong buy, 7 buy, 6 hold, 2 sell, and 4 strong sell
